Pharming Group

Pharming appoints Dr. Perry Calias chief scientific officer

Thursday, February 19, 2015

Pharming Group has appointed Dr. Perry Calias chief scientific officer. Calias will have overall responsibility for the company’s new enzyme replacement therapy (ERT) programs, achieving the scientific milestones set in the business plan, enhancing the IP portfolio, overseeing new product development and contributing to the overall strategic direction of the company.

[Read More]